At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 161 enrolled
Drug / intervention
Placebo comparator +1 moredrug
Likely dose
risedronate 35 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D-Peripheral Quantitative Computed Tomography (3D-pQCT)
In Brief
A Phase 3 clinical trial evaluating Placebo comparator and risedronate for Osteopenia. Completed, enrolled 161 participants across 9 sites in 7 countries.
Detailed Summary
The primary purpose of the protocol is to evaluate the sensitivity of 3D-pQCT (3D-Peripheral Quantitative Computed Tomography) technology to detect minute changes in bone microarchitecture.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteopenia
CountriesArgentina, Australia, Canada, France, Germany, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedOct 2006
Primary CompletionSep 2009
TodayJul 2026
First PostedOct 11, 2006
Enrollment StartApr 1, 2006
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 19.7 years ago
Interventions
Placebo comparatordrug
oral weekly for one year
risedronatedrug
35 mg risedronate, once a week for one year